RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaN/A

Registered title, quoted from ClinicalTrials.gov

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Huadong Hospital, Fudan University; 1 other hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Huadong Hospital, Fudan University复旦大学附属华东医院ShanghaiHospital page
  2. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04519905, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 76 years to Not stated; sex: all

    Registered eligibility fields

  2. Esophageal squamous cell carcinoma confirmed by pathology

    Inclusion criterion 3

  3. Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, TxNxM1b (M1b only for supraclavicular lymph node metastasis) (AJCC 6th)

    Inclusion criterion 5

  4. ECOG 0-1.

    Inclusion criterion 9

  5. History of prior malignancies (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years)

    Exclusion criterion 5

  6. Use of an effective contraceptive for adults to prevent pregnancy

    Inclusion criterion 6

    Pregnant or breast-feeding women or fertile patients

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04519905, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Indicates no limit on eligibility based on the sex of participants
  • The 76 years old for the minimum age a potential participant must meet to be eligible for the clinical study.
  • Esophageal squamous cell carcinoma confirmed by pathology
  • No radiotherapy, chemotherapy or other treatments prior to enrollment
  • Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, TxNxM1b (M1b only for supraclavicular lymph node metastasis) (AJCC 6th)
  • Use of an effective contraceptive for adults to prevent pregnancy
  • No severely abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function
  • No immunodeficiency
  • ECOG 0-1.
  • Life expectancy of more than 3 months.

Exclusion Criteria:

  • Total radiotherapy dose cannot reach 61.2Gy/34Fx
  • Esophageal perforation, or hematemesis
  • History of radiotherapy or chemotherapy for esophageal cancer
  • History of surgery within 28 days before Day 1
  • History of prior malignancies (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years)
  • Participation in other interventional clinical trials within 30 days
  • Pregnant or breast-feeding women or fertile patients
  • Drug addiction,
  • alcoholism or AIDS
  • Uncontrolled seizures or psychiatric disorders

Quoted from ClinicalTrials.gov, NCT04519905, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04519905, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04519905